Blood DNA test to detect leftover cancer in esophageal, stomach and pancreatic cancer
Tests a blood DNA test for cancer return in digestive tract cancers.
Plain-language title generated from the registry record
Registry title: Determining Minimal Residual Disease Using ctDNA Deep Sequencing
Key facts
- Where
- Brno, CzechiaSee the site
Where in Czechia
- Masaryk Memorial Cancer InstituteBrno, CzechiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Masaryk Memorial Cancer Institute
- Trial code
- NCT07660627
- Record updated
- 24 June 2026
- Original description
Preoperative neoadjuvant chemotherapy is the standard treatment for locally advanced gastrointestinal tumours. However, not all patients respond to preoperative treatment. Early identification of progression during neoadjuvant chemotherapy or diagnosis of early disease relapse during adjuvant treatment is essential to modify the treatment strategy. The aim of this project is to validate ctDNA as a biomarker of molecular relapse/progression of disease.Read full original descriptionShow less
Determination of Minimal Residual Disease by Deep ctDNA Sequencing.
Preoperative neoadjuvant chemotherapy is the standard treatment for locally advanced gastrointestinal tumours. However, not all patients respond to preoperative treatment. Early identification of progression during neoadjuvant chemotherapy or diagnosis of early disease relapse during adjuvant treatment is essential to modify the treatment strategy. The aim of this project is to validate ctDNA as a biomarker of molecular relapse/progression of disease.
Inclusion: Consent to participate in the study; Patients with esophageal, gastric, or pancreatic cancer, stage 0-2; Patients with locally advanced, potentially operable disease treated with systemic perioperative chemotherapy or chemoradiotherapy; Patients with metastatic disease treated with first- to third-line palliative systemic therapy.
Exclusion: not specified.